Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424892 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT00424892: Completed Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00424892 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 600 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00424892, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
Interventions
- DRUG Desvenlafaxine Sustained Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00424892 record still lists
NCT00424892 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher).
The record links to 0 conditions, and to 1 intervention - of which Desvenlafaxine Sustained Release is the first listed.
NCT00424892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00424892 about?
NCT00424892 is a clinical study titled "Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome". The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
What is the current status of trial NCT00424892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00424892?
The interventions under investigation include: Desvenlafaxine Sustained Release (DRUG).
Who is sponsoring clinical trial NCT00424892?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00424892's enrollment target sits among peer trials
600 53rd of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging